Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-Exo for Large and Refractory Macular Holes
NCT03437759Phase 1Unknown
- Sponsor
- Tianjin Medical University
- Start
- Mar 2017
- Primary completion
- May 2018
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mesenchymal stem cell exosomes in macular hole (2 arms), sponsored by Tianjin Medical University. Primary endpoint: Macular holes closure at 24 weeks. Status: unknown.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
macular hole
Beyond the preview
Go deeper on NCT03437759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437759.